Ulrich Jäger, MD, Medical University of Vienna, Vienna, Austria, gives an overview of the topics discussed in the session he chaired on practical aspects of CAR T-cell therapy. CAR T-cell immunotherapy has radically altered the treatment of B-cell malignancies. Prof. Jäger outlines that in the setting of diffuse large B-cell lymphoma, the approved CAR-T products are being integrated into daily clinical practice. However, patient selection remains a challenge in the field. The new and exciting field of BCMA CAR T-cells in multiple myeloma was also addressed during the session. This interview took place during the 3rd European CAR T-cell Meeting.
Grant, personal fees, and nonfinancial support from Novartis, Bristol Myers Squibb/Celgene, Gilead, Janssen, Merck, and Roche
Grant and personal fees from Sanofi
Personal fees and nonfinancial support from AbbVie, Amgen, AOP Orphan, Miltenyi Biotec, Sandoz, and Takeda